WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation

Core Insights - Aquablation therapy shows comparable symptom relief to laser enucleation while significantly preserving ejaculatory function and continence in patients with large prostates [1][2][4] Group 1: Study Overview - The WATER III trial is an international, prospective, multicenter study comparing Aquablation therapy to laser enucleation for prostate sizes between 80-180 mL, involving 186 men treated from December 2020 to September 2024 [2] - The study reported three-month primary safety and efficacy endpoints, with plans to follow patients for five years [2] Group 2: Clinical Outcomes - Aquablation therapy resulted in a 14.8% rate of ejaculatory dysfunction compared to 77.1% for laser enucleation, and a 0% rate of stress incontinence compared to 9.1% for laser enucleation [2] - The procedural transfusion rate for Aquablation therapy was 0%, indicating a strong safety profile in managing bleeding risk [3] Group 3: Expert Commentary - The CEO of PROCEPT BioRobotics emphasized that the results of the WATER III trial reinforce the company's commitment to establishing Aquablation therapy as the standard of care for BPH, highlighting its effectiveness in preserving quality of life factors [4] - Dr. Naeem Bhojani noted that the consistent efficacy and lower rates of complications represent a significant advancement for patients seeking BPH treatment [4] Group 4: Technology and Innovation - Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for BPH, allowing for personalized treatment planning based on real-time imaging [5] - The technology enables precise and controlled removal of prostate tissue while preserving critical anatomical structures [5] Group 5: Company Background - PROCEPT BioRobotics is focused on advancing patient care through innovative urology solutions, manufacturing the AQUABEAM and HYDROS Robotic Systems [6] - The company has developed a substantial body of clinical evidence, including over 150 peer-reviewed publications, supporting the benefits of Aquablation therapy [7]